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Efficacy and Safety of Tocilizumab in the 
Treatment of Acute Active Antibody-mediated 
Rejection in Kidney Transplant Recipients
April A. Pottebaum, PharmD, BCPS,1 Karthikeyan Venkatachalam, MD,2 Chang Liu, MD, PhD,3  
Daniel C. Brennan, MD,4 Haris Murad, MD,2 Andrew F. Malone, MB, BCh,2 and Tarek Alhamad, MD, MS2
Antibody-mediated rejection (AMR) continues to have a deleterious impact on kidney allograft survival.1 
Current evidence for treatment of acute active AMR is lim-
ited, but treatment recommendations were recently released. 
The 2019 Expert Consensus from the Transplantation Society 
Working Group described the combination of plasmapheresis 
(PP), IVIG, and steroids as the standard of care for most cases 
of acute active AMR and highlighted that adjunctive therapies 
may also be considered depending on the clinical situation. 
This group also indicated that new agents and adequately 
powered clinical trials are urgently needed to improve patient 
outcomes.2
Recently, there has been interest in targeting interleukin 
6 (IL-6). Interleukin 6 mediates various inflammatory and 
immunomodulatory pathways. Notably, in kidney trans-
plantation, it is critical for expansion and activation of T 
cells and B cells. Evidence suggests IL-6 controls prolifera-
tion and survival of T-cells, including Tfh and Th17 cells, and 
also inhibits Treg cell function. Furthermore, IL-6 controls 
progression of naïve B cells and plasmablasts into mature 
plasma cells.3
Tocilizumab, an IL-6 receptor antagonist, has been eval-
uated in the treatment of chronic, active AMR (cAMR) 
with positive donor-specific antibodies (DSAs) and trans-
plant glomerulopathy resistant to traditional treatment 
with IVIG and rituximab with and without PP. The study 
showed a stabilization of renal function over 2 y, and a 
significant reduction of glomerulitis, peritubular capil-
laritis, C4d deposition, and DSAs. However, no decrease 
in transplant glomerulopathy was observed.4 Given these 
findings, there is interest in using tocilizumab for acute 
active AMR.
Here, we report 7 cases that received tocilizumab for treat-
ment of acute active AMR. Tocilizumab was used in addition 
to conventional therapies.
Kidney Transplantation
Background. Antibody-mediated rejection (AMR) continues to have a deleterious impact on kidney allograft survival. 
Recent evidence supports use of tocilizumab for treatment of chronic active AMR, but it has not been assessed for treatment 
of acute active AMR. Methods. We performed a single-center, observational study of kidney transplant recipients who 
received at least 1 dose of tocilizumab in addition to conventional therapies for acute active AMR between October 2016 
and October 2018 with follow-up through August 2019. Results. Seven patients were included. All 7 patients received 
tocilizumab 8 mg/kg (max dose, 800 mg) monthly. We noted a 50% or greater reduction in immunodominant donor-specific 
antibodies in 4 of 6 patients. Renal function improved or stabilized in all patients throughout the duration of therapy. One 
patient developed cytomegalovirus esophagitis and 1 had a potential hypersensitivity reaction. In the extended follow-up, 
1 patient had mixed rejection and 2 patients had T-cell–mediated rejection, which occurred 6 to 24 mo after completion of 
therapy. Conclusions. Tocilizumab may be considered as an addition to conventional therapies for treatment of acute 
active AMR. More studies are needed to determine which patients may benefit from therapy and to examine the appropriate 
duration of treatment.
(Transplantation Direct 2020;6: e543; doi: 10.1097/TXD.0000000000000988. Published online 13 March, 2020.)
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MATERIALS AND METHODS
We performed a retrospective chart review of kidney trans-
plant recipients at Barnes-Jewish Hospital/Washington 
University Transplant Center who received at least 1 dose 
of tocilizumab for treatment of acute active AMR between 
October 2016 and October 2018. We excluded all patients 
with chronic glomerulopathy (cG) >1. Patients were fol-
lowed through August 2019. Information about baseline 
demographics, pertinent comorbidities, and transplant 
characteristics was recorded. All patients had a renal allo-
graft biopsy performed at the time of rejection diagnosis. 
DSA testing was also performed at this time and during 
follow-up by single-antigen bead assay (One Lambda, 
West Hills, CA). All serum samples were pretreated with 
ethylenediaminetetraacetic acid.5 A mean fluorescence 
intensity (MFI) cutoff value of 1000 was used to classify 
positive DSA, and an MFI >2000 correlates with a posi-
tive flow cytometric crossmatch (FCXM) at our center.6 
For each patient, the immunodominant DSA was defined 
as the specificity with the highest MFI among all donor-
specific reactivities.
RESULTS
All patients received induction with lymphocyte-depleting 
agents at the time of kidney transplantation, and all patients 
were maintained on triple immunosuppression with cal-
cineurin inhibitor, antimetabolite, and prednisone at the time 
of AMR diagnosis. Baseline characteristics are summarized 
in Table 1.
All patients received tocilizumab in addition to conven-
tional treatments for AMR. Tocilizumab was dosed at 8 mg/
kg (max dose, 800 mg) IV monthly. Treatment duration was 
determined based on patient-specific factors, with treatment 
duration ranging from 1 to 6 doses. Median duration of treat-
ment was 4 mo.
Table 2 shows the Banff scoring system in all biopsies before 
use of tocilizumab. The majority of patients had high-level 
DSAs at the time of biopsy. There was a 50% or greater reduc-
tion in immunodominant DSA in 4 of 6 patients who had 
repeat DSA testing following use of tocilizumab. Furthermore, 
renal function improved or stabilized in all patients (Table 3).
All cases are discussed in detail below.
Case 1
Thirty-five-year-old Caucasian woman with end-stage renal 
disease (ESRD) secondary to congenital renal hypoplasia. She 
underwent living donor renal transplant (LDRT) in 1995, 
which failed in 1997 after excessive bleeding related to a 
biopsy. She then underwent deceased donor renal transplant 
(DDRT) in August 1997, which failed in November 1998 
secondary to acute rejection. She received another DDRT 
in March 2017. HLA mismatch was 2A/0B/0DR. cPRA was 
100%, with positive T-cell and B-cell FCXM. DSA screen was 
negative. She received induction with Thymoglobulin 5 mg/
kg and a single dose of rituximab. She was discharged with 
serum creatinine (SCr) of 0.87 mg/dL.
Two mo after transplant, she developed AKI with SCr of 
1.5 mg/dL. Allograft biopsy revealed acute active AMR and 
borderline acute cellular rejection (ACR). C4d staining was 
negative. She had new DSA to DR51 (MFI: 4960) and A11 
(MFI: 2142). She received a prednisone burst and tocili-
zumab. Upon discharge, the plan was to continue monthly 
tocilizumab for 6 mo.
Before the third dose of tocilizumab, the patient reported 
persistent gastric reflux. Esophagogastroduodenoscopy 
showed cytomegalovirus (CMV) esophagitis. Valganciclovir 
was initiated, and tocilizumab was discontinued. When tocili-
zumab therapy concluded, her renal function had returned to 
baseline. DSA screen showed a reduction in the level of DSA 
to DR51 (MFI: 2165).
Her renal function remained stable for nearly 18 mo after dis-
continuation of tocilizumab until she was readmitted with SCr 
>10 mg/dL in December 2018. Allograft biopsy revealed ACR, 
Banff IIA. DSA screen showed DSA to DR51 (MFI: 1264). She 
received bolus steroids and Thymoglobulin, but her renal func-
tion did not recover and she was placed on hemodialysis.
Case 2
Thirty-five-year-old Filipino woman with ESRD second-
ary to biopsy-proven IgA nephropathy. She underwent LDRT 
from her husband in 2007, which failed in 2009 secondary to 
chronic rejection. She then underwent DDRT in October 2016. 
HLA mismatch was 0A/2B/2DR. cPRA was 100%, with nega-
tive T-cell and B-cell FCXM. DSA screen was negative. She 
received induction with basiliximab followed by alemtuzumab. 
Her postoperative course was complicated by slow graft func-
tion, and she was discharged on POD 8 with SCr of 2 mg/dL.
She was readmitted 4 d later with SCr of 5.4 mg/dL. She 
had new DSA against B51 (MFI: 24 085), B53 (MFI: 20 801), 
DQ2 (MFI: 14 965), DR13 (MFI: 9857), C6 (MFI: 6603), and 
DR7 (MFI: 4541). Allograft biopsy revealed acute active AMR 
with thrombotic microangiopathy. C4d staining was diffusely 
positive. She was initially treated with bolus steroids, PP, and 
IVIG. She also received eculizumab and rituximab. Following 
these therapies, a repeat allograft biopsy was performed. 
TABLE 1.
Baseline characteristics
ID Age, y Race Sex Cause of ESRD Type of transplant Mismatch A/B/DR Previous transplant Induction IS Maintenance IS
1 35 C F Congenital hypoplasia DDRT 2/0/0 Yes Thymoglobulin Tac, MPA, Pred
2 35 Fi F IgA DDRT 0/2/2 Yes Basiliximab + alemtuzumab Tac, MPA, Pred
3 43 AA F Lupus DDRT 1/2/1 No Thymoglobulin Tac, AZA, Pred
4 39 C M FSGS LDRT 1/1/1 No Thymoglobulin Tac, MPA, Pred
5 63 C M GN DDRT 2/1/1 Yes Thymoglobulin Tac, MPA, Pred
6 51 C M Alport syndrome DDRT 1/1/2 Yes Thymoglobulin Tac, MPA, Pred
7 34 AA F Solitary kidney LDRT 0/2/2 No Thymoglobulin CsA, MPA, Pred
AA, African American; AZA, azathioprine; C, Caucasian; CsA, cyclosporine; DDRT, deceased donor renal transplant; ESRD, end-stage renal disease; F, female; Fi, Filipino; FSGS, focal segmental glo-
merulosclerosis; GN, glomerulonephritis; IS, immunosuppression; LDRT, living donor renal transplant; M, male; MPA, mycophenolic acid; Pred, prednisone; Tac, tacrolimus.
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There was mildly increased capillary loop thickness and acute 
tubular necrosis, but no light microscopy evidence of AMR. 
Nevertheless, based on previous biopsy findings, diffusely 
positive C4d staining, and presence of DSAs, she was deemed 
to have acute AMR. At this time, tocilizumab was initiated. 
The patient’s SCr decreased, and she was discharged with SCr 
of 3.0 mg/dL. Upon discharge, the plan was to continue twice 
weekly PP, monthly IVIG, and monthly tocilizumab.
PP was discontinued after 2 mo because of line-associated 
bacteremia. Both IVIG and tocilizumab were discontinued 
after 3 mo. At the completion of therapy, her SCr had returned 
to baseline of ~2.0 mg/dL, and her DSAs had decreased signifi-
cantly. DSA to B51 decreased from 24 085 to 5064. DSA to 
B53 decreased from 20 801 to 2719.
The patient did well for 6 mo until she was admitted to a 
different medical center with SCr of ~6.0 mg/dL in July 2017. 
Allograft biopsy showed ACR, Banff IB, with moderate glomer-
ulitis and minimal peritubular capillaritis. She received bolus 
steroids and Atgam, but her SCr remained elevated at 5–6 mg/
dL. She received 1 additional dose of tocilizumab in August 2017 
before it was discontinued because of low likelihood of clinical 
response. She was initiated on hemodialysis in November 2017.
Case 3
Forty-three-year-old African American woman with ESRD 
secondary to lupus nephritis. She underwent DDRT in 
November 2009. HLA mismatch was 1A/2B/1DR. T-cell and 
B-cell FCXM were negative. Induction was Thymoglobulin 
5 mg/kg. Baseline SCr was 1.0–1.2 mg/dL.
In June 2017, she developed AKI with SCr of 3.5 mg/dL. 
Allograft biopsy revealed ACR, Banff IB, with increased 
plasma cells; acute active AMR; focal global glomerulosclero-
sis 9 of 32 (28%); and moderate interstitial fibrosis. C4d stain-
ing was focally positive. She had DSA to DQ6 (MFI: 20 400), 
DR51 (MFI: 17 524), C7 (MFI: 2402), and B53 (MFI: 1528). 
She did not undergo PP because of difficult access. Instead, 
she received bolus steroids, Thymoglobulin, IVIG, and toci-
lizumab. Her SCr decreased, and she was discharged with 
SCr of 2.1 mg/dL. Upon discharge, the plan was to continue 
monthly tocilizumab for 6 mo.
After the third dose of tocilizumab, she developed dyspnea. 
Diphenhydramine and acetaminophen were administered. She 
subsequently became unresponsive. Epinephrine was admin-
istered, and cardiopulmonary resuscitation was commenced. 
She was revived without requiring intubation. The syncope 
was attributed to an adverse reaction from tocilizumab or 
intravenous diphenhydramine. Because of the uncertainty of 
this reaction, subsequent tocilizumab infusions were discon-
tinued. Her SCr stabilized around 2.0 mg/dL.
Approximately 24 mo later, she presented with AKI with 
SCr of 5.2 mg/dL in the setting of medication noncompli-
ance. Allograft biopsy showed ACR, Banff IB. C4d stain-
ing was negative. She had DSA to DQ6 (MFI: 10 414) and 
DR51 (MFI: 16 746). Bolus steroids and Thymoglobulin were 
administered, and her SCr decreased to 3.5 mg/dL.
Case 4
Thirty-nine-year-old Caucasian man with ESRD secondary 
to biopsy-proven focal segmental glomerulosclerosis (FSGS). He 
underwent LDRT from his mother in July 2015. It was a 1-hap-
lotype match. T-cell and B-cell FCXM were negative. Induction 
was Thymoglobulin 5 mg/kg. Baseline SCr was 1.6 mg/dL.
In January 2018, he developed new onset proteinuria of 1.8 
g. Allograft biopsy showed PTC3, g2, and cG1. C4d staining 
was negative. He had new DSA against DQ7 (MFI: 12 662), 
so he was considered to have AMR. He received bolus ster-
oids, PP, IVIG, bortezomib, rituximab, and tocilizumab. Upon 
TABLE 2.
Pathology: Banff scoring of kidney transplant biopsies 
before use of tocilizumab
ID PTC G cG T cT I cI C4d
1 PTC2 G1 cG0 T2 cT0 I1 cI0 Negative
2 PTC0 G0 cG0 T0 cT0 I0 cI0 Positive
3 PTC3 G0 cG0 T3 cT1 I3 cI2 Positive
4 PTC3 G2 cG1 T0 cT0 I0 cI0 Negative
5 PTC2 G1 cG0 T0 cT1 I0 cI1 Positive
6 PTC3 G1 cG0 T1 cT1 I1 cI1 Negative
7 PTC3 G1 cG0 T3 cT1 I2 cI1 Negative
cG, chronic glomerulopathy; cI, interstitial fibrosis; cT, tubular atrophy; G, glomerulitis; I, interstitial 
inflammation; PTC, peritubular capillaritis; T, tubulitis.
TABLE 3.
Clinical and laboratory characteristics
ID














Reason for Toci 
discontinuation Follow-up outcomes
1 Acute AMR + 
borderline ACR
0.9–1.0 1.5 DR51; 4960 DR51; 2165 0.9 2 CMV esophagitis T-cell mediated rejection 
after 18 mo with return 
to dialysis
2 Acute AMR 2.0 5.4 B51; 24 085 B51; 5064 1.9 3 + 1 Therapy completed; 
futile
Mixed rejection after 6 mo 
with return to dialysis
3 Acute AMR + ACR 
(1B)
1.0–1.2 3.5 DQ6; 20 400 DQ6; 16 824 2.0 3 Potential hypersensi-
tivity reaction
T-cell mediated rejection 
after 24 mo with 
noncompliance
4 Chronic active AMR 1.6 1.7 + proteinuria DQ7; 12 662 DQ7; 5893 1.7–2.0 6 Therapy completed Stable renal function
5 Acute AMR 2.8–3.3 6.6 DQA1; 11 891 Not checked 4.0–5.0 1 Medical comorbidities Stable renal function
6 Acute AMR +  
borderline ACR
2.2–2.5 2.3 C8; 1849 Not present 2.2–2.5 6 Therapy completed Stable renal function
7 AMR + ACR (1B) 1.1–1.2 1.8 DQ7; 24 042 DQ7; 24 647 1.8 4 Papillary thyroid 
carcinoma
Stable renal function
ACR, acute cellular rejection; AMR, antibody-mediated rejection; CMV, cytomegalovirus; iDSA, immunodominant donor specific antibody; MFI, mean fluorescence intensity; SCr, serum creatinine; Toci, 
tocilizumab.
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discharge, the plan was to continue monthly tocilizumab for 
6 mo.
He completed 6 mo of tocilizumab. His SCr was stable 
at 1.7–2.0 mg/dL throughout treatment with proteinuria 
<0.5 g. An interim biopsy in March 2018 showed FSGS, 69% 
global glomerulosclerosis, and severe interstitial fibrosis. 
Approximately 1 mo after treatment concluded, proteinuria 
increased to ~1.5 g and then reached 5.4 g in December 2018. 
A repeat biopsy showed PTC0, g2, cG1, and FSGS (8/20). C4d 
staining was negative. ACTH gel was initiated with rising pro-
teinuria but was subsequently discontinued because of intol-
erance. Thus, lisinopril was maximized. SCr has remained 
stable around 2 mg/dL and proteinuria has been stable around 
1 g for the past 10 mo.
Case 5
Sixty-three-year-old Caucasian man with ESRD secondary 
to unspecified glomerulonephritis. He underwent LDRT from 
his sister in 1991, who was lost in 2017 because of chronic 
allograft nephropathy. He then underwent DDRT in February 
2018. HLA mismatch was 2A/1B/1DR. cPRA was 74%, with 
negative cytotoxicity crossmatch and positive B-cell FCXM. 
He had DSA to DQA1*02:01 (MFI: 15 877), C5 (MFI: 3076), 
and DR7 (MFI: 2194). Induction was Thymoglobulin 5 mg/
kg. He also received PP, rituximab, and bortezomib. His post-
operative course was complicated by delayed graft function. 
Allograft biopsy performed on POD 13 showed acute tubu-
lar injury and mild glomerulitis. C4d staining was negative. 
His SCr continued to decrease with baseline SCr noted to be 
2.8–3.3 mg/dL.
Two months after transplant, he developed AKI with SCr 
of 6.6 mg/dL and worsening proteinuria. Allograft biopsy 
revealed active AMR. Minimal C4d staining in peritubular 
capillaries (<10%) was observed. He had persistent DSA to 
DQA1*02:01 (MFI: 11 891). He received bolus steroids, PP, 
IVIG, rituximab, and tocilizumab. His SCr decreased, and he 
was discharged with SCr of 4.4 mg/dL.
Within 2 wk of discharge, he was readmitted with hema-
tochezia. Notably, he was taking warfarin for atrial fibril-
lation. Colonoscopy revealed several sites with ulceration 
and exposed visible vessel throughout the distal transverse, 
descending, sigmoid colon, and rectum. Hospital course 
was complicated by pancytopenia, aspiration pneumonia, 
and abdominal abscess. Further treatments for rejection 
were not pursued because of his medical comorbidities. His 
SCr has remained stable around 3.5–4.0 mg/dL for the past 
18 mo.
Case 6
Fifty-one-year-old Caucasian man with ESRD secondary 
to Alport syndrome. He underwent DDRT in 2007, which 
was complicated by rejection and return to dialysis in 2014. 
He received a second DDRT in June 2017. HLA mismatch 
was 1A/1B/2DR. cPRA was 87%, with negative T-cell and 
B-cell FCXM. He had DSA to C8 (MFI: 2356). Induction 
was Thymoglobulin 5 mg/kg. He was discharged with SCr of 
1.9 mg/dL.
Two months after transplant, he developed AKI with SCr of 
4.8 mg/dL. Allograft biopsy revealed acute active AMR. C4d 
staining was negative. He had DSA to C8 (MFI: 3698), DR14 
(MFI: 1032), and DR15 (MFI: 1112). He received bolus ster-
oids, PP, and study medication (C1 esterase inhibitor versus 
placebo). His SCr decreased, and he was discharged with SCr 
of 2.7 mg/dL.
Approximately 6 mo after this episode of AMR, repeat allo-
graft biopsy showed acute active AMR and borderline ACR. 
C4d staining was negative. He had DSA to C8 (MFI: 1849), 
DR14 (MFI: 1090), and DR15 (MFI: 1193). He received 
bolus steroids, PP, IVIG, rituximab, and tocilizumab.
He completed 6 mo of tocilizumab as planned. Upon com-
pletion of therapy, DSA screen was negative. His SCr has 
remained stable at 2.2–2.5 mg/dL for the past 15 mo.
Case 7
Thirty-four-year-old African American woman with ESRD 
secondary to solitary kidney and proteinuria. She under-
went LDRT from a friend in June 2012. HLA mismatch was 
0A/2B/2DR. T-cell and B-cell FCXM were negative. Induction 
was Thymoglobulin 5 mg/kg. Baseline SCr was 1.1–1.2 mg/dL.
In April 2018, she developed AKI with SCr of 1.8 mg/
dL in the setting of medication noncompliance. Allograft 
biopsy revealed active AMR; ACR, Banff IB; and moderate 
IFTA. C4d staining was negative. She had DSA to DQ7 (MFI: 
23 344). She received bolus steroids, PP, IVIG, Thymoglobulin, 
and rituximab. Despite these therapies, her DSAs remained 
unchanged (MFI: 24 042), and her SCr remained elevated 
around 1.8 mg/dL.
In June 2018, tocilizumab was initiated. Around this same 
time, a mass was found on the right anterior neck. Biopsy 
revealed papillary thyroid carcinoma, and she underwent 
total thyroidectomy. Given the newly diagnosed cancer, toci-
lizumab and mycophenolic acid were discontinued. She ulti-
mately received 4 doses of tocilizumab. Her DSAs remained 
unchanged and SCr remained stable for the past 12 mo.
DISCUSSION
AMR can have detrimental effects on allograft survival and 
quality of life for kidney transplant recipients. PP, IVIG, and 
steroids have become the standard of care, yet these strategies 
have not proven to be adequate for treatment of AMR.2
Tocilizumab has previously been studied in the treatment 
of cAMR. In that study of 36 patients who failed standard 
therapy for cAMR, significant reductions in immunodomi-
nant DSAs and stabilization of renal function were seen at 
2 y. Furthermore, tocilizumab-treated patients demonstrated 
graft survival and patient survival rates of 80% and 91% at 
6 y, respectively.4
Our study provides novel insight on use of tocilizumab in 
patients presenting with acute active AMR. Patients with acute 
active AMR have an increased risk of chronic AMR and graft 
loss.7 Thus, treatment strategies aimed at removing circulating 
DSAs and/or reducing DSA production may be beneficial in 
this population to delay or prevent progression. Conventional 
therapy with PP followed by IVIG has been shown to reduce 
DSA levels by 15%–35% depending on HLA DSA specificity 
and number of PP sessions.8 Therefore, we deemed a 50% 
reduction in DSA levels to be clinically meaningful. In the pre-
sent study, a 50% or greater reduction in immunodominant 
DSA was observed in 4 of 6 patients, and DSA stabilized in 
all other patients. Furthermore, renal function improved or 
stabilized in all patients during therapy.
In terms of efficacy, 1 patient experienced mixed rejec-
tion 6 mo after completion of tocilizumab, while 2 others 
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experienced ACR at 18 and 24 mo after medication discon-
tinuation. Two of these patients ultimately returned to dialysis 
secondary to these recurrent rejection episodes. It should be 
noted that all patients who experienced rejection received ≤3 
doses of tocilizumab with their initial course. Rebound IL-6 
activity after stopping tocilizumab has been suggested in stud-
ies using it for desensitization, although the clinical signifi-
cance remains unknown.9 Our early experience suggests that 
ongoing treatment may be warranted with tocilizumab.
Adverse events were noted in our case series, although these 
events could not be attributed directly to tocilizumab since 
patients also received other conventional therapies. In the 
study by Choi et al, infectious adverse events were reported 
in 13 of 36 patients, but all infectious events resolved with 
directed treatment and without the need to discontinue 
tocilizumab.4 In our case series, 1 patient developed CMV 
esophagitis, which was successfully treated with oral valgan-
ciclovir. Notably, this patient had a history of CMV viremia 
before use of tocilizumab. One patient also experienced a 
potential hypersensitivity reaction. Although uncommon, 
hypersensitivity reactions have been reported in association 
with tocilizumab.10
Several limitations of our study require consideration. The 
study is limited by the small cohort size, the heterogeneity 
of the patient population, and the absence of a comparator 
group. Furthermore, treatment for AMR at our institution 
is not managed by standardized protocols. Given that all 
patients received other conventional therapies, it was difficult 
to assess the contribution of tocilizumab to overall efficacy. 
Additionally, although a reduction in DSA levels was noted 
for several patients, some DSAs remained strong enough to 
cause a positive FCXM. Our study is also limited by the lack 
of protocol biopsies following use of tocilizumab, although 
several patients had a repeat biopsy performed when they pre-
sented with additional episodes of AKI.
In summary, our study provides novel insight into the use 
of tocilizumab for treatment of acute active AMR. Further 
studies are needed to better define the role of tocilizumab in 
this context. Our early experience suggests clinicians should 
give careful consideration to longer durations of therapy.
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